OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $3.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 105.48% from the company’s current price.

OPK has been the topic of several other reports. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd.

OPKO Health Stock Down 4.6 %

Shares of NASDAQ:OPK opened at $1.46 on Monday. The firm has a market cap of $980.46 million, a PE ratio of -7.68 and a beta of 1.78. The company has a fifty day simple moving average of $1.69 and a 200 day simple moving average of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a 12-month low of $1.15 and a 12-month high of $2.04.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. On average, equities research analysts anticipate that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the company’s stock in a transaction on Friday, January 17th. The shares were bought at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the purchase, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This trade represents a 0.07 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased 1,339,971 shares of company stock worth $2,098,692 in the last 90 days. 49.69% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OPKO Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC raised its stake in OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after acquiring an additional 329,870 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 217,450 shares in the last quarter. FMR LLC lifted its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Y Intercept Hong Kong Ltd bought a new position in OPKO Health in the 4th quarter valued at about $102,000. Finally, Essential Planning LLC. acquired a new position in OPKO Health during the 4th quarter valued at about $506,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.